LONDON (Alliance News) - 4D Pharma PLC said Friday the UK Medicines & Healthcare Products Regulatory Agency has granted approval for 4D's phase I clinical study of Thetanix in pediatric Crohn's disease to be restarted.
The trial had been delayed as a precaution due to concerns about quality that had come to light at one of 4D's supply partners during the manufacture of an additional batch of Thetanix.
4D Pharma said that its own investigation into the matter had been completed.
Shares in 4D Pharma were up 2.6% at 880.00 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
